While cardiovascular disease may be common and commonly known to patients, they may not know some of the surprising factors in their diet and medical history that may actually be putting them at risk. What are some of the cardiovascular disease risk factors patients should know about?
February is AMD and Low Vision Awareness Month. There are several modifications patients can make to their lifestyles that may help reduce their risk of AMD.
Since January is National Birth Defects Prevention Month, it represents an opportune time to inform pregnant patients and their families about some lesser-known risks for birth defects that may help to improve neonatal outcomes.
The FDA has approved Trulicity (dulaglutide; Lilly) to reduce the risk of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction [MI], or nonfatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
The FDA has approved Anjeso (meloxicam injection; Baudax Bio) for the management of moderate to severe pain, alone or in combination with NSAIDs in adult patients.
Among systemic treatments for plaque psoriasis, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were found to be associated with the highest Psoriasis Area and Severity Index (PASI) response rates.
Clinicians should discuss alternative weight-loss medications and strategies with patients.
A recent systematic review identified several established as well as emerging practices utilized in the pediatric setting that were associated with overuse of medical care.
Higher doses anti-tumor necrosis factor-α (anti-TNF-α) therapy may be neceessary for obese patients with ulcerative colitis (UC), according to the findings of a recently published meta-analysis.
Yesterday, the World Health Organization gave the virus a new name: COVID-19.
Please login or register first to view this content.
